SCHEMBL5058345

SCHEMBL5058345

O=C(O)CNC(=O)CP(O)(O)=S

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.36
EGLN1 Q9GZT9 2/20 0.35
ITGB1 P05556 1/20 0.35
ITGA5 P08648 1/20 0.35
TDP1 Q9NUW8 3/20 0.34
LMNA P02545 2/20 0.34
MAPT P10636 2/20 0.34
PTGS2 P35354 1/20 0.34
FAAH O00519 5/20 0.34
MEN1 O00255 3/20 0.33
KMT2A Q03164 3/20 0.33
HPGD P15428 2/20 0.33
BLM P54132 2/20 0.33
TSHR P16473 1/20 0.33
ABAT P80404 1/20 0.33
PTPN1 P18031 1/20 0.33
APEX1 P27695 2/20 0.33
KDM4E B2RXH2 1/20 0.33
USP2 O75604 1/20 0.33
POLB P06746 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5058493 0.79 LMNA (0.52) ALDH1A1EGLN1ITGB1ITGA5TDP1
SCHEMBL5058343 0.76 ALDH1A1 (0.38) ALDH1A1EGLN1ITGB1ITGA5TDP1
SCHEMBL2807522 0.72 EGLN1 (0.46) ALDH1A1EGLN1ITGB1ITGA5TDP1
SCHEMBL29590 0.72
SCHEMBL5058344 0.71 EGLN1 (0.35) ALDH1A1EGLN1ITGB1ITGA5TDP1
SCHEMBL5063494 0.70
SCHEMBL5059570 0.70
SCHEMBL6471153 0.69 LDHA (0.47) ALDH1A1EGLN1ITGB1ITGA5TDP1
SCHEMBL4817231 0.67
SCHEMBL3051875 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080317834-A1 Compounds and methods for modulating cerebral amyloid angiopathy NEUROCHEM (INTERNATIONAL) LIMITED (CH) 2008-12-25 US disclosed
US-20080317834-A1 Compounds and methods for modulating cerebral amyloid angiopathy NEUROCHEM (INTERNATIONAL) LIMITED (CH) 2008-12-25 US disclosed
US-20080317834-A1 Compounds and methods for modulating cerebral amyloid angiopathy NEUROCHEM (INTERNATIONAL) LIMITED (CH) 2008-12-25 US disclosed
US-20070078082-A1 Methods and compositions to treat glycosaminoglycan-associated molecular interactions NEUROCHEM (INTERNATIONAL) LIMITED (CH) 2007-04-05 US disclosed
US-20070078082-A1 Methods and compositions to treat glycosaminoglycan-associated molecular interactions NEUROCHEM (INTERNATIONAL) LIMITED (CH) 2007-04-05 US disclosed
US-6670399-B2 Contacting a blood vessel wall cell with an A beta 40 inhibitor, such that cerebral amyloid angiopathy is inhibited NEUROCHEM (INTERNATIONAL) LIMITED (CH) 2003-12-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080317834-A1 Compounds and methods for modulating cerebral amyloid angiopathy APP, PYGB, MAPT ALDH1A1 3580/4885EGLN1 1312/4885ITGB1 3154/4885
US-20070078082-A1 Methods and compositions to treat glycosaminoglycan-associated molecular interactions HPSE, CD44, CSGALNACT1 ALDH1A1 2097/4885EGLN1 1042/4885ITGB1 502/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.